nodes	percent_of_prediction	percent_of_DWPC	metapath
Acamprosate—GRIN2C—CREB phosphorylation through the activation of Ras—BRAF—colon cancer	0.00297	0.0261	CbGpPWpGaD
Acamprosate—GRIN2D—CREB phosphorylation through the activation of Ras—BRAF—colon cancer	0.00276	0.0242	CbGpPWpGaD
Acamprosate—GRIN2C—Post NMDA receptor activation events—BRAF—colon cancer	0.00244	0.0215	CbGpPWpGaD
Acamprosate—GRIN2D—Post NMDA receptor activation events—BRAF—colon cancer	0.00227	0.0199	CbGpPWpGaD
Acamprosate—GRIN2A—CREB phosphorylation through the activation of Ras—BRAF—colon cancer	0.00226	0.0199	CbGpPWpGaD
Acamprosate—GRIN2C—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—colon cancer	0.00225	0.0198	CbGpPWpGaD
Acamprosate—GRIN2D—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—colon cancer	0.00209	0.0184	CbGpPWpGaD
Acamprosate—GRIN1—CREB phosphorylation through the activation of Ras—BRAF—colon cancer	0.00198	0.0174	CbGpPWpGaD
Acamprosate—GRIN2B—CREB phosphorylation through the activation of Ras—BRAF—colon cancer	0.00193	0.0169	CbGpPWpGaD
Acamprosate—GRIN2C—Ras activation uopn Ca2+ infux through NMDA receptor—HRAS—colon cancer	0.00191	0.0168	CbGpPWpGaD
Acamprosate—GRIN2A—Post NMDA receptor activation events—BRAF—colon cancer	0.00186	0.0164	CbGpPWpGaD
Acamprosate—Renal failure acute—Methotrexate—colon cancer	0.00185	0.00209	CcSEcCtD
Acamprosate—Leukopenia—Irinotecan—colon cancer	0.00185	0.00209	CcSEcCtD
Acamprosate—Convulsion—Vincristine—colon cancer	0.00184	0.00208	CcSEcCtD
Acamprosate—Hypertension—Vincristine—colon cancer	0.00183	0.00207	CcSEcCtD
Acamprosate—Anaemia—Fluorouracil—colon cancer	0.00183	0.00207	CcSEcCtD
Acamprosate—Loss of consciousness—Irinotecan—colon cancer	0.00182	0.00205	CcSEcCtD
Acamprosate—Dermatitis exfoliative—Methotrexate—colon cancer	0.00181	0.00205	CcSEcCtD
Acamprosate—Photosensitivity reaction—Capecitabine—colon cancer	0.00181	0.00205	CcSEcCtD
Acamprosate—Myalgia—Vincristine—colon cancer	0.00181	0.00204	CcSEcCtD
Acamprosate—Weight increased—Capecitabine—colon cancer	0.00181	0.00204	CcSEcCtD
Acamprosate—Cough—Irinotecan—colon cancer	0.0018	0.00204	CcSEcCtD
Acamprosate—Weight decreased—Capecitabine—colon cancer	0.0018	0.00203	CcSEcCtD
Acamprosate—Hyperglycaemia—Capecitabine—colon cancer	0.00179	0.00202	CcSEcCtD
Acamprosate—Hypertension—Irinotecan—colon cancer	0.00179	0.00201	CcSEcCtD
Acamprosate—Pneumonia—Capecitabine—colon cancer	0.00178	0.00201	CcSEcCtD
Acamprosate—GRIN2D—Ras activation uopn Ca2+ infux through NMDA receptor—HRAS—colon cancer	0.00178	0.0156	CbGpPWpGaD
Acamprosate—Leukopenia—Fluorouracil—colon cancer	0.00177	0.002	CcSEcCtD
Acamprosate—Depression—Capecitabine—colon cancer	0.00177	0.00199	CcSEcCtD
Acamprosate—Acute coronary syndrome—Capecitabine—colon cancer	0.00175	0.00197	CcSEcCtD
Acamprosate—Discomfort—Irinotecan—colon cancer	0.00174	0.00196	CcSEcCtD
Acamprosate—Myocardial infarction—Capecitabine—colon cancer	0.00174	0.00196	CcSEcCtD
Acamprosate—Anaphylactic shock—Vincristine—colon cancer	0.00173	0.00196	CcSEcCtD
Acamprosate—Stomatitis—Capecitabine—colon cancer	0.00173	0.00195	CcSEcCtD
Acamprosate—Infection—Vincristine—colon cancer	0.00172	0.00194	CcSEcCtD
Acamprosate—Urinary tract infection—Capecitabine—colon cancer	0.00172	0.00194	CcSEcCtD
Acamprosate—GRIN2A—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—colon cancer	0.00172	0.0151	CbGpPWpGaD
Acamprosate—Convulsion—Fluorouracil—colon cancer	0.00172	0.00194	CcSEcCtD
Acamprosate—Confusional state—Irinotecan—colon cancer	0.0017	0.00192	CcSEcCtD
Acamprosate—Thrombocytopenia—Vincristine—colon cancer	0.0017	0.00191	CcSEcCtD
Acamprosate—Haematuria—Capecitabine—colon cancer	0.00169	0.00191	CcSEcCtD
Acamprosate—Anaphylactic shock—Irinotecan—colon cancer	0.00169	0.0019	CcSEcCtD
Acamprosate—Myalgia—Fluorouracil—colon cancer	0.00169	0.0019	CcSEcCtD
Acamprosate—Chest pain—Fluorouracil—colon cancer	0.00169	0.0019	CcSEcCtD
Acamprosate—Infection—Irinotecan—colon cancer	0.00168	0.00189	CcSEcCtD
Acamprosate—Hyperhidrosis—Vincristine—colon cancer	0.00167	0.00189	CcSEcCtD
Acamprosate—Epistaxis—Capecitabine—colon cancer	0.00167	0.00188	CcSEcCtD
Acamprosate—Discomfort—Fluorouracil—colon cancer	0.00167	0.00188	CcSEcCtD
Acamprosate—Shock—Irinotecan—colon cancer	0.00166	0.00187	CcSEcCtD
Acamprosate—Thrombocytopenia—Irinotecan—colon cancer	0.00165	0.00186	CcSEcCtD
Acamprosate—Anorexia—Vincristine—colon cancer	0.00165	0.00186	CcSEcCtD
Acamprosate—Hyperhidrosis—Irinotecan—colon cancer	0.00163	0.00184	CcSEcCtD
Acamprosate—Confusional state—Fluorouracil—colon cancer	0.00163	0.00184	CcSEcCtD
Acamprosate—GRIN1—Post NMDA receptor activation events—BRAF—colon cancer	0.00163	0.0143	CbGpPWpGaD
Acamprosate—Hypotension—Vincristine—colon cancer	0.00162	0.00183	CcSEcCtD
Acamprosate—Anaphylactic shock—Fluorouracil—colon cancer	0.00162	0.00182	CcSEcCtD
Acamprosate—Anorexia—Irinotecan—colon cancer	0.00161	0.00181	CcSEcCtD
Acamprosate—Infection—Fluorouracil—colon cancer	0.00161	0.00181	CcSEcCtD
Acamprosate—Haemoglobin—Capecitabine—colon cancer	0.0016	0.0018	CcSEcCtD
Acamprosate—Rhinitis—Capecitabine—colon cancer	0.00159	0.0018	CcSEcCtD
Acamprosate—Hepatitis—Capecitabine—colon cancer	0.00159	0.00179	CcSEcCtD
Acamprosate—Haemorrhage—Capecitabine—colon cancer	0.00159	0.00179	CcSEcCtD
Acamprosate—GRIN2B—Post NMDA receptor activation events—BRAF—colon cancer	0.00158	0.0139	CbGpPWpGaD
Acamprosate—Thrombocytopenia—Fluorouracil—colon cancer	0.00158	0.00179	CcSEcCtD
Acamprosate—Hypoaesthesia—Capecitabine—colon cancer	0.00158	0.00178	CcSEcCtD
Acamprosate—Liver function test abnormal—Methotrexate—colon cancer	0.00158	0.00178	CcSEcCtD
Acamprosate—Musculoskeletal discomfort—Vincristine—colon cancer	0.00158	0.00178	CcSEcCtD
Acamprosate—Pharyngitis—Capecitabine—colon cancer	0.00158	0.00178	CcSEcCtD
Acamprosate—Tachycardia—Fluorouracil—colon cancer	0.00158	0.00178	CcSEcCtD
Acamprosate—Hypotension—Irinotecan—colon cancer	0.00158	0.00178	CcSEcCtD
Acamprosate—Insomnia—Vincristine—colon cancer	0.00157	0.00177	CcSEcCtD
Acamprosate—Oedema peripheral—Capecitabine—colon cancer	0.00157	0.00177	CcSEcCtD
Acamprosate—Paraesthesia—Vincristine—colon cancer	0.00156	0.00176	CcSEcCtD
Acamprosate—Breast disorder—Methotrexate—colon cancer	0.00155	0.00174	CcSEcCtD
Acamprosate—Anorexia—Fluorouracil—colon cancer	0.00154	0.00174	CcSEcCtD
Acamprosate—Visual impairment—Capecitabine—colon cancer	0.00153	0.00173	CcSEcCtD
Acamprosate—Insomnia—Irinotecan—colon cancer	0.00153	0.00172	CcSEcCtD
Acamprosate—Paraesthesia—Irinotecan—colon cancer	0.00152	0.00171	CcSEcCtD
Acamprosate—Hypotension—Fluorouracil—colon cancer	0.00151	0.0017	CcSEcCtD
Acamprosate—Decreased appetite—Vincristine—colon cancer	0.00151	0.0017	CcSEcCtD
Acamprosate—Dyspnoea—Irinotecan—colon cancer	0.0015	0.0017	CcSEcCtD
Acamprosate—Somnolence—Irinotecan—colon cancer	0.0015	0.00169	CcSEcCtD
Acamprosate—GRIN1—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—colon cancer	0.0015	0.0132	CbGpPWpGaD
Acamprosate—Gastrointestinal disorder—Vincristine—colon cancer	0.0015	0.00169	CcSEcCtD
Acamprosate—Dyspepsia—Irinotecan—colon cancer	0.00149	0.00168	CcSEcCtD
Acamprosate—Tinnitus—Capecitabine—colon cancer	0.00148	0.00167	CcSEcCtD
Acamprosate—Constipation—Vincristine—colon cancer	0.00148	0.00167	CcSEcCtD
Acamprosate—Pain—Vincristine—colon cancer	0.00148	0.00167	CcSEcCtD
Acamprosate—Asthma—Methotrexate—colon cancer	0.00148	0.00167	CcSEcCtD
Acamprosate—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.00147	0.00166	CcSEcCtD
Acamprosate—Decreased appetite—Irinotecan—colon cancer	0.00147	0.00166	CcSEcCtD
Acamprosate—Eosinophilia—Methotrexate—colon cancer	0.00146	0.00165	CcSEcCtD
Acamprosate—Insomnia—Fluorouracil—colon cancer	0.00146	0.00165	CcSEcCtD
Acamprosate—GRIN2A—Ras activation uopn Ca2+ infux through NMDA receptor—HRAS—colon cancer	0.00146	0.0128	CbGpPWpGaD
Acamprosate—GRIN2B—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—colon cancer	0.00146	0.0128	CbGpPWpGaD
Acamprosate—Gastrointestinal disorder—Irinotecan—colon cancer	0.00146	0.00164	CcSEcCtD
Acamprosate—Paraesthesia—Fluorouracil—colon cancer	0.00145	0.00164	CcSEcCtD
Acamprosate—Pancreatitis—Methotrexate—colon cancer	0.00145	0.00164	CcSEcCtD
Acamprosate—Pain—Irinotecan—colon cancer	0.00144	0.00163	CcSEcCtD
Acamprosate—Constipation—Irinotecan—colon cancer	0.00144	0.00163	CcSEcCtD
Acamprosate—Dyspnoea—Fluorouracil—colon cancer	0.00144	0.00163	CcSEcCtD
Acamprosate—Somnolence—Fluorouracil—colon cancer	0.00144	0.00162	CcSEcCtD
Acamprosate—Immune system disorder—Capecitabine—colon cancer	0.00144	0.00162	CcSEcCtD
Acamprosate—Chills—Capecitabine—colon cancer	0.00143	0.00161	CcSEcCtD
Acamprosate—Dyspepsia—Fluorouracil—colon cancer	0.00142	0.00161	CcSEcCtD
Acamprosate—Gastrointestinal pain—Vincristine—colon cancer	0.00142	0.0016	CcSEcCtD
Acamprosate—Decreased appetite—Fluorouracil—colon cancer	0.0014	0.00159	CcSEcCtD
Acamprosate—Alopecia—Capecitabine—colon cancer	0.0014	0.00159	CcSEcCtD
Acamprosate—Gastrointestinal disorder—Fluorouracil—colon cancer	0.0014	0.00157	CcSEcCtD
Acamprosate—Mental disorder—Capecitabine—colon cancer	0.00139	0.00157	CcSEcCtD
Acamprosate—Feeling abnormal—Irinotecan—colon cancer	0.00139	0.00157	CcSEcCtD
Acamprosate—Malnutrition—Capecitabine—colon cancer	0.00138	0.00156	CcSEcCtD
Acamprosate—Pain—Fluorouracil—colon cancer	0.00138	0.00156	CcSEcCtD
Acamprosate—Gastrointestinal pain—Irinotecan—colon cancer	0.00138	0.00156	CcSEcCtD
Acamprosate—Body temperature increased—Vincristine—colon cancer	0.00137	0.00155	CcSEcCtD
Acamprosate—Abdominal pain—Vincristine—colon cancer	0.00137	0.00155	CcSEcCtD
Acamprosate—GRIN2C—CREB phosphorylation through the activation of Ras—HRAS—colon cancer	0.00136	0.012	CbGpPWpGaD
Acamprosate—Flatulence—Capecitabine—colon cancer	0.00136	0.00154	CcSEcCtD
Acamprosate—Erectile dysfunction—Methotrexate—colon cancer	0.00136	0.00154	CcSEcCtD
Acamprosate—Dysgeusia—Capecitabine—colon cancer	0.00136	0.00153	CcSEcCtD
Acamprosate—Photosensitivity reaction—Methotrexate—colon cancer	0.00135	0.00152	CcSEcCtD
Acamprosate—Back pain—Capecitabine—colon cancer	0.00134	0.00151	CcSEcCtD
Acamprosate—Abdominal pain—Irinotecan—colon cancer	0.00133	0.00151	CcSEcCtD
Acamprosate—Body temperature increased—Irinotecan—colon cancer	0.00133	0.00151	CcSEcCtD
Acamprosate—Feeling abnormal—Fluorouracil—colon cancer	0.00133	0.0015	CcSEcCtD
Acamprosate—Muscle spasms—Capecitabine—colon cancer	0.00133	0.0015	CcSEcCtD
Acamprosate—Pneumonia—Methotrexate—colon cancer	0.00133	0.0015	CcSEcCtD
Acamprosate—Depression—Methotrexate—colon cancer	0.00131	0.00148	CcSEcCtD
Acamprosate—Tremor—Capecitabine—colon cancer	0.0013	0.00146	CcSEcCtD
Acamprosate—Stomatitis—Methotrexate—colon cancer	0.00128	0.00145	CcSEcCtD
Acamprosate—Ill-defined disorder—Capecitabine—colon cancer	0.00128	0.00145	CcSEcCtD
Acamprosate—Urticaria—Fluorouracil—colon cancer	0.00128	0.00145	CcSEcCtD
Acamprosate—Anaemia—Capecitabine—colon cancer	0.00128	0.00144	CcSEcCtD
Acamprosate—Body temperature increased—Fluorouracil—colon cancer	0.00128	0.00144	CcSEcCtD
Acamprosate—Hypersensitivity—Vincristine—colon cancer	0.00128	0.00144	CcSEcCtD
Acamprosate—GRIN1—Ras activation uopn Ca2+ infux through NMDA receptor—HRAS—colon cancer	0.00127	0.0112	CbGpPWpGaD
Acamprosate—GRIN2D—CREB phosphorylation through the activation of Ras—HRAS—colon cancer	0.00127	0.0111	CbGpPWpGaD
Acamprosate—Sweating—Methotrexate—colon cancer	0.00126	0.00143	CcSEcCtD
Acamprosate—Haematuria—Methotrexate—colon cancer	0.00126	0.00142	CcSEcCtD
Acamprosate—Malaise—Capecitabine—colon cancer	0.00125	0.00141	CcSEcCtD
Acamprosate—Epistaxis—Methotrexate—colon cancer	0.00124	0.0014	CcSEcCtD
Acamprosate—Vertigo—Capecitabine—colon cancer	0.00124	0.0014	CcSEcCtD
Acamprosate—Hypersensitivity—Irinotecan—colon cancer	0.00124	0.0014	CcSEcCtD
Acamprosate—Asthenia—Vincristine—colon cancer	0.00124	0.0014	CcSEcCtD
Acamprosate—GRIN2B—Ras activation uopn Ca2+ infux through NMDA receptor—HRAS—colon cancer	0.00124	0.0109	CbGpPWpGaD
Acamprosate—Syncope—Capecitabine—colon cancer	0.00124	0.0014	CcSEcCtD
Acamprosate—Leukopenia—Capecitabine—colon cancer	0.00124	0.0014	CcSEcCtD
Acamprosate—Palpitations—Capecitabine—colon cancer	0.00122	0.00138	CcSEcCtD
Acamprosate—Loss of consciousness—Capecitabine—colon cancer	0.00122	0.00137	CcSEcCtD
Acamprosate—Asthenia—Irinotecan—colon cancer	0.00121	0.00137	CcSEcCtD
Acamprosate—Cough—Capecitabine—colon cancer	0.00121	0.00136	CcSEcCtD
Acamprosate—Hypertension—Capecitabine—colon cancer	0.00119	0.00135	CcSEcCtD
Acamprosate—Hypersensitivity—Fluorouracil—colon cancer	0.00119	0.00134	CcSEcCtD
Acamprosate—Haemoglobin—Methotrexate—colon cancer	0.00119	0.00134	CcSEcCtD
Acamprosate—Diarrhoea—Vincristine—colon cancer	0.00119	0.00134	CcSEcCtD
Acamprosate—Haemorrhage—Methotrexate—colon cancer	0.00118	0.00134	CcSEcCtD
Acamprosate—Hepatitis—Methotrexate—colon cancer	0.00118	0.00134	CcSEcCtD
Acamprosate—Arthralgia—Capecitabine—colon cancer	0.00118	0.00133	CcSEcCtD
Acamprosate—Chest pain—Capecitabine—colon cancer	0.00118	0.00133	CcSEcCtD
Acamprosate—Myalgia—Capecitabine—colon cancer	0.00118	0.00133	CcSEcCtD
Acamprosate—Pharyngitis—Methotrexate—colon cancer	0.00117	0.00133	CcSEcCtD
Acamprosate—Anxiety—Capecitabine—colon cancer	0.00117	0.00132	CcSEcCtD
Acamprosate—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.00117	0.00132	CcSEcCtD
Acamprosate—Discomfort—Capecitabine—colon cancer	0.00116	0.00131	CcSEcCtD
Acamprosate—GRIN2A—Reelin signaling pathway—PIK3CA—colon cancer	0.00116	0.0102	CbGpPWpGaD
Acamprosate—Diarrhoea—Irinotecan—colon cancer	0.00115	0.0013	CcSEcCtD
Acamprosate—Dry mouth—Capecitabine—colon cancer	0.00115	0.0013	CcSEcCtD
Acamprosate—Dizziness—Vincristine—colon cancer	0.00115	0.00129	CcSEcCtD
Acamprosate—Pruritus—Fluorouracil—colon cancer	0.00114	0.00129	CcSEcCtD
Acamprosate—Visual impairment—Methotrexate—colon cancer	0.00114	0.00129	CcSEcCtD
Acamprosate—Confusional state—Capecitabine—colon cancer	0.00114	0.00128	CcSEcCtD
Acamprosate—GRIN2C—Post NMDA receptor activation events—HRAS—colon cancer	0.00112	0.00986	CbGpPWpGaD
Acamprosate—Infection—Capecitabine—colon cancer	0.00112	0.00127	CcSEcCtD
Acamprosate—Dizziness—Irinotecan—colon cancer	0.00112	0.00126	CcSEcCtD
Acamprosate—Shock—Capecitabine—colon cancer	0.00111	0.00125	CcSEcCtD
Acamprosate—Diarrhoea—Fluorouracil—colon cancer	0.00111	0.00125	CcSEcCtD
Acamprosate—Thrombocytopenia—Capecitabine—colon cancer	0.00111	0.00125	CcSEcCtD
Acamprosate—Tinnitus—Methotrexate—colon cancer	0.0011	0.00124	CcSEcCtD
Acamprosate—Tachycardia—Capecitabine—colon cancer	0.0011	0.00124	CcSEcCtD
Acamprosate—Vomiting—Vincristine—colon cancer	0.0011	0.00124	CcSEcCtD
Acamprosate—Skin disorder—Capecitabine—colon cancer	0.0011	0.00124	CcSEcCtD
Acamprosate—Rash—Vincristine—colon cancer	0.00109	0.00123	CcSEcCtD
Acamprosate—Hyperhidrosis—Capecitabine—colon cancer	0.00109	0.00123	CcSEcCtD
Acamprosate—Dermatitis—Vincristine—colon cancer	0.00109	0.00123	CcSEcCtD
Acamprosate—Headache—Vincristine—colon cancer	0.00109	0.00122	CcSEcCtD
Acamprosate—Anorexia—Capecitabine—colon cancer	0.00108	0.00121	CcSEcCtD
Acamprosate—Vomiting—Irinotecan—colon cancer	0.00107	0.00121	CcSEcCtD
Acamprosate—Immune system disorder—Methotrexate—colon cancer	0.00107	0.00121	CcSEcCtD
Acamprosate—Dizziness—Fluorouracil—colon cancer	0.00107	0.00121	CcSEcCtD
Acamprosate—Rash—Irinotecan—colon cancer	0.00106	0.0012	CcSEcCtD
Acamprosate—Dermatitis—Irinotecan—colon cancer	0.00106	0.0012	CcSEcCtD
Acamprosate—Chills—Methotrexate—colon cancer	0.00106	0.0012	CcSEcCtD
Acamprosate—Headache—Irinotecan—colon cancer	0.00106	0.00119	CcSEcCtD
Acamprosate—Hypotension—Capecitabine—colon cancer	0.00106	0.00119	CcSEcCtD
Acamprosate—Alopecia—Methotrexate—colon cancer	0.00105	0.00118	CcSEcCtD
Acamprosate—GRIN2D—Post NMDA receptor activation events—HRAS—colon cancer	0.00104	0.00917	CbGpPWpGaD
Acamprosate—GRIN2A—CREB phosphorylation through the activation of Ras—HRAS—colon cancer	0.00104	0.00915	CbGpPWpGaD
Acamprosate—Mental disorder—Methotrexate—colon cancer	0.00104	0.00117	CcSEcCtD
Acamprosate—GRIN2C—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—colon cancer	0.00103	0.00909	CbGpPWpGaD
Acamprosate—Malnutrition—Methotrexate—colon cancer	0.00103	0.00116	CcSEcCtD
Acamprosate—Nausea—Vincristine—colon cancer	0.00103	0.00116	CcSEcCtD
Acamprosate—Musculoskeletal discomfort—Capecitabine—colon cancer	0.00103	0.00116	CcSEcCtD
Acamprosate—Vomiting—Fluorouracil—colon cancer	0.00103	0.00116	CcSEcCtD
Acamprosate—Insomnia—Capecitabine—colon cancer	0.00102	0.00115	CcSEcCtD
Acamprosate—Rash—Fluorouracil—colon cancer	0.00102	0.00115	CcSEcCtD
Acamprosate—Dermatitis—Fluorouracil—colon cancer	0.00102	0.00115	CcSEcCtD
Acamprosate—Paraesthesia—Capecitabine—colon cancer	0.00101	0.00114	CcSEcCtD
Acamprosate—Headache—Fluorouracil—colon cancer	0.00101	0.00114	CcSEcCtD
Acamprosate—Dysgeusia—Methotrexate—colon cancer	0.00101	0.00114	CcSEcCtD
Acamprosate—Dyspnoea—Capecitabine—colon cancer	0.00101	0.00114	CcSEcCtD
Acamprosate—Nausea—Irinotecan—colon cancer	0.001	0.00113	CcSEcCtD
Acamprosate—GRIN2C—Alzheimers Disease—CASP3—colon cancer	0.000998	0.00877	CbGpPWpGaD
Acamprosate—Back pain—Methotrexate—colon cancer	0.000996	0.00112	CcSEcCtD
Acamprosate—Dyspepsia—Capecitabine—colon cancer	0.000994	0.00112	CcSEcCtD
Acamprosate—GRIN2B—Reelin signaling pathway—PIK3CA—colon cancer	0.000984	0.00865	CbGpPWpGaD
Acamprosate—Decreased appetite—Capecitabine—colon cancer	0.000982	0.00111	CcSEcCtD
Acamprosate—GRIN1—EPHB-mediated forward signaling—SRC—colon cancer	0.000978	0.0086	CbGpPWpGaD
Acamprosate—Gastrointestinal disorder—Capecitabine—colon cancer	0.000975	0.0011	CcSEcCtD
Acamprosate—Constipation—Capecitabine—colon cancer	0.000966	0.00109	CcSEcCtD
Acamprosate—Pain—Capecitabine—colon cancer	0.000966	0.00109	CcSEcCtD
Acamprosate—GRIN2D—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—colon cancer	0.000961	0.00845	CbGpPWpGaD
Acamprosate—Nausea—Fluorouracil—colon cancer	0.00096	0.00108	CcSEcCtD
Acamprosate—Ill-defined disorder—Methotrexate—colon cancer	0.000956	0.00108	CcSEcCtD
Acamprosate—GRIN2B—EPHB-mediated forward signaling—SRC—colon cancer	0.000954	0.00838	CbGpPWpGaD
Acamprosate—Anaemia—Methotrexate—colon cancer	0.000952	0.00107	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—DLC1—colon cancer	0.000948	0.00833	CbGpPWpGaD
Acamprosate—GRIN2A—Reelin signaling pathway—AKT1—colon cancer	0.000946	0.00831	CbGpPWpGaD
Acamprosate—Feeling abnormal—Capecitabine—colon cancer	0.000931	0.00105	CcSEcCtD
Acamprosate—Malaise—Methotrexate—colon cancer	0.000929	0.00105	CcSEcCtD
Acamprosate—GRIN2D—Alzheimers Disease—CASP3—colon cancer	0.000928	0.00815	CbGpPWpGaD
Acamprosate—Vertigo—Methotrexate—colon cancer	0.000925	0.00104	CcSEcCtD
Acamprosate—Gastrointestinal pain—Capecitabine—colon cancer	0.000923	0.00104	CcSEcCtD
Acamprosate—Leukopenia—Methotrexate—colon cancer	0.000922	0.00104	CcSEcCtD
Acamprosate—GRIN1—CREB phosphorylation through the activation of Ras—HRAS—colon cancer	0.000908	0.00798	CbGpPWpGaD
Acamprosate—Cough—Methotrexate—colon cancer	0.000899	0.00101	CcSEcCtD
Acamprosate—Urticaria—Capecitabine—colon cancer	0.000897	0.00101	CcSEcCtD
Acamprosate—Abdominal pain—Capecitabine—colon cancer	0.000893	0.00101	CcSEcCtD
Acamprosate—Body temperature increased—Capecitabine—colon cancer	0.000893	0.00101	CcSEcCtD
Acamprosate—Convulsion—Methotrexate—colon cancer	0.000893	0.00101	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—LGR5—colon cancer	0.000892	0.00784	CbGpPWpGaD
Acamprosate—GRIN2B—CREB phosphorylation through the activation of Ras—HRAS—colon cancer	0.000885	0.00778	CbGpPWpGaD
Acamprosate—Chest pain—Methotrexate—colon cancer	0.000877	0.00099	CcSEcCtD
Acamprosate—Myalgia—Methotrexate—colon cancer	0.000877	0.00099	CcSEcCtD
Acamprosate—Arthralgia—Methotrexate—colon cancer	0.000877	0.00099	CcSEcCtD
Acamprosate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.000871	0.000983	CcSEcCtD
Acamprosate—Discomfort—Methotrexate—colon cancer	0.000866	0.000978	CcSEcCtD
Acamprosate—GRIN2A—Post NMDA receptor activation events—HRAS—colon cancer	0.000857	0.00753	CbGpPWpGaD
Acamprosate—Confusional state—Methotrexate—colon cancer	0.000848	0.000957	CcSEcCtD
Acamprosate—GRIN2C—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—colon cancer	0.000842	0.0074	CbGpPWpGaD
Acamprosate—Anaphylactic shock—Methotrexate—colon cancer	0.000841	0.000949	CcSEcCtD
Acamprosate—Infection—Methotrexate—colon cancer	0.000835	0.000942	CcSEcCtD
Acamprosate—Hypersensitivity—Capecitabine—colon cancer	0.000832	0.000939	CcSEcCtD
Acamprosate—GRIN2B—ErbB4 signaling events—PIK3CA—colon cancer	0.000823	0.00724	CbGpPWpGaD
Acamprosate—Thrombocytopenia—Methotrexate—colon cancer	0.000823	0.000929	CcSEcCtD
Acamprosate—Skin disorder—Methotrexate—colon cancer	0.000817	0.000921	CcSEcCtD
Acamprosate—Hyperhidrosis—Methotrexate—colon cancer	0.000813	0.000917	CcSEcCtD
Acamprosate—Asthenia—Capecitabine—colon cancer	0.00081	0.000914	CcSEcCtD
Acamprosate—GRIN1—Axon guidance—DCC—colon cancer	0.000805	0.00707	CbGpPWpGaD
Acamprosate—GRIN2B—Reelin signaling pathway—AKT1—colon cancer	0.000804	0.00707	CbGpPWpGaD
Acamprosate—Anorexia—Methotrexate—colon cancer	0.000801	0.000904	CcSEcCtD
Acamprosate—Pruritus—Capecitabine—colon cancer	0.000799	0.000902	CcSEcCtD
Acamprosate—GRIN2A—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—colon cancer	0.000789	0.00694	CbGpPWpGaD
Acamprosate—Hypotension—Methotrexate—colon cancer	0.000786	0.000886	CcSEcCtD
Acamprosate—GRIN2B—Axon guidance—DCC—colon cancer	0.000785	0.0069	CbGpPWpGaD
Acamprosate—GRIN2D—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—colon cancer	0.000783	0.00688	CbGpPWpGaD
Acamprosate—Diarrhoea—Capecitabine—colon cancer	0.000773	0.000872	CcSEcCtD
Acamprosate—Musculoskeletal discomfort—Methotrexate—colon cancer	0.000766	0.000864	CcSEcCtD
Acamprosate—GRIN2A—Alzheimers Disease—CASP3—colon cancer	0.000762	0.00669	CbGpPWpGaD
Acamprosate—Insomnia—Methotrexate—colon cancer	0.00076	0.000858	CcSEcCtD
Acamprosate—Paraesthesia—Methotrexate—colon cancer	0.000755	0.000852	CcSEcCtD
Acamprosate—Dyspnoea—Methotrexate—colon cancer	0.00075	0.000846	CcSEcCtD
Acamprosate—GRIN1—Post NMDA receptor activation events—HRAS—colon cancer	0.000747	0.00657	CbGpPWpGaD
Acamprosate—Somnolence—Methotrexate—colon cancer	0.000747	0.000843	CcSEcCtD
Acamprosate—Dizziness—Capecitabine—colon cancer	0.000747	0.000843	CcSEcCtD
Acamprosate—Dyspepsia—Methotrexate—colon cancer	0.00074	0.000835	CcSEcCtD
Acamprosate—Decreased appetite—Methotrexate—colon cancer	0.000731	0.000825	CcSEcCtD
Acamprosate—GRIN2B—Post NMDA receptor activation events—HRAS—colon cancer	0.000729	0.0064	CbGpPWpGaD
Acamprosate—Gastrointestinal disorder—Methotrexate—colon cancer	0.000726	0.000819	CcSEcCtD
Acamprosate—Pain—Methotrexate—colon cancer	0.000719	0.000811	CcSEcCtD
Acamprosate—Vomiting—Capecitabine—colon cancer	0.000718	0.00081	CcSEcCtD
Acamprosate—Rash—Capecitabine—colon cancer	0.000712	0.000804	CcSEcCtD
Acamprosate—Dermatitis—Capecitabine—colon cancer	0.000711	0.000803	CcSEcCtD
Acamprosate—Headache—Capecitabine—colon cancer	0.000707	0.000798	CcSEcCtD
Acamprosate—Feeling abnormal—Methotrexate—colon cancer	0.000693	0.000782	CcSEcCtD
Acamprosate—GRIN1—EPHB-mediated forward signaling—HRAS—colon cancer	0.000689	0.00605	CbGpPWpGaD
Acamprosate—GRIN1—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—colon cancer	0.000689	0.00605	CbGpPWpGaD
Acamprosate—Gastrointestinal pain—Methotrexate—colon cancer	0.000687	0.000776	CcSEcCtD
Acamprosate—GRIN2B—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—colon cancer	0.000671	0.0059	CbGpPWpGaD
Acamprosate—GRIN2B—EPHB-mediated forward signaling—HRAS—colon cancer	0.000671	0.0059	CbGpPWpGaD
Acamprosate—Nausea—Capecitabine—colon cancer	0.000671	0.000757	CcSEcCtD
Acamprosate—Urticaria—Methotrexate—colon cancer	0.000668	0.000754	CcSEcCtD
Acamprosate—Abdominal pain—Methotrexate—colon cancer	0.000665	0.00075	CcSEcCtD
Acamprosate—Body temperature increased—Methotrexate—colon cancer	0.000665	0.00075	CcSEcCtD
Acamprosate—GRIN1—Alzheimers Disease—CASP3—colon cancer	0.000664	0.00584	CbGpPWpGaD
Acamprosate—GRIN2B—Alzheimers Disease—CASP3—colon cancer	0.000648	0.00569	CbGpPWpGaD
Acamprosate—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—colon cancer	0.000643	0.00565	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—AXIN2—colon cancer	0.000641	0.00563	CbGpPWpGaD
Acamprosate—GRIN2C—Alzheimers Disease—TP53—colon cancer	0.00064	0.00562	CbGpPWpGaD
Acamprosate—GRIN2C—Transmission across Chemical Synapses—BRAF—colon cancer	0.000633	0.00556	CbGpPWpGaD
Acamprosate—Hypersensitivity—Methotrexate—colon cancer	0.000619	0.000699	CcSEcCtD
Acamprosate—Asthenia—Methotrexate—colon cancer	0.000603	0.000681	CcSEcCtD
Acamprosate—Pruritus—Methotrexate—colon cancer	0.000595	0.000671	CcSEcCtD
Acamprosate—GRIN2D—Alzheimers Disease—TP53—colon cancer	0.000595	0.00523	CbGpPWpGaD
Acamprosate—GRIN2D—Transmission across Chemical Synapses—BRAF—colon cancer	0.000588	0.00517	CbGpPWpGaD
Acamprosate—GRM5—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—colon cancer	0.000587	0.00516	CbGpPWpGaD
Acamprosate—GRIN1—BDNF signaling pathway—APC—colon cancer	0.000583	0.00513	CbGpPWpGaD
Acamprosate—Diarrhoea—Methotrexate—colon cancer	0.000575	0.000649	CcSEcCtD
Acamprosate—GRIN1—Developmental Biology—DCC—colon cancer	0.000574	0.00505	CbGpPWpGaD
Acamprosate—GRIN2B—BDNF signaling pathway—APC—colon cancer	0.000569	0.005	CbGpPWpGaD
Acamprosate—GRIN1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—colon cancer	0.000561	0.00493	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—DCC—colon cancer	0.00056	0.00492	CbGpPWpGaD
Acamprosate—Dizziness—Methotrexate—colon cancer	0.000556	0.000627	CcSEcCtD
Acamprosate—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—colon cancer	0.000547	0.0048	CbGpPWpGaD
Acamprosate—GRM5—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—colon cancer	0.000535	0.0047	CbGpPWpGaD
Acamprosate—Vomiting—Methotrexate—colon cancer	0.000535	0.000603	CcSEcCtD
Acamprosate—Rash—Methotrexate—colon cancer	0.00053	0.000598	CcSEcCtD
Acamprosate—Dermatitis—Methotrexate—colon cancer	0.00053	0.000598	CcSEcCtD
Acamprosate—Headache—Methotrexate—colon cancer	0.000527	0.000594	CcSEcCtD
Acamprosate—GRIN1—Spinal Cord Injury—PTGS2—colon cancer	0.000519	0.00456	CbGpPWpGaD
Acamprosate—GRM5—G alpha (q) signalling events—PIK3CA—colon cancer	0.000519	0.00456	CbGpPWpGaD
Acamprosate—GRM5—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—colon cancer	0.000505	0.00444	CbGpPWpGaD
Acamprosate—GRIN1—EPH-Ephrin signaling—SRC—colon cancer	0.000504	0.00443	CbGpPWpGaD
Acamprosate—Nausea—Methotrexate—colon cancer	0.000499	0.000563	CcSEcCtD
Acamprosate—GRIN2B—EPH-Ephrin signaling—SRC—colon cancer	0.000491	0.00432	CbGpPWpGaD
Acamprosate—GRIN1—EPH-Ephrin signaling—VEGFA—colon cancer	0.000491	0.00431	CbGpPWpGaD
Acamprosate—GRIN2A—Alzheimers Disease—TP53—colon cancer	0.000488	0.00429	CbGpPWpGaD
Acamprosate—GRIN2C—Neuronal System—BRAF—colon cancer	0.000485	0.00426	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—HNF4A—colon cancer	0.000484	0.00425	CbGpPWpGaD
Acamprosate—GRIN2A—Transmission across Chemical Synapses—BRAF—colon cancer	0.000483	0.00425	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—CASP3—colon cancer	0.000482	0.00424	CbGpPWpGaD
Acamprosate—GRIN2B—EPH-Ephrin signaling—VEGFA—colon cancer	0.000478	0.0042	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—HNF4A—colon cancer	0.000471	0.00414	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—CCND1—colon cancer	0.000469	0.00412	CbGpPWpGaD
Acamprosate—GRM5—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—colon cancer	0.000464	0.00408	CbGpPWpGaD
Acamprosate—SLC36A1—Transmembrane transport of small molecules—ABCB1—colon cancer	0.000456	0.00401	CbGpPWpGaD
Acamprosate—GRIN2D—Neuronal System—BRAF—colon cancer	0.000451	0.00396	CbGpPWpGaD
Acamprosate—GRM5—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—colon cancer	0.000429	0.00377	CbGpPWpGaD
Acamprosate—GRIN1—Alzheimers Disease—TP53—colon cancer	0.000426	0.00374	CbGpPWpGaD
Acamprosate—GRIN1—Transmission across Chemical Synapses—BRAF—colon cancer	0.000421	0.0037	CbGpPWpGaD
Acamprosate—GRIN2B—Alzheimers Disease—TP53—colon cancer	0.000415	0.00365	CbGpPWpGaD
Acamprosate—GRIN1—BDNF signaling pathway—CASP3—colon cancer	0.000411	0.00361	CbGpPWpGaD
Acamprosate—GRIN2B—Transmission across Chemical Synapses—BRAF—colon cancer	0.000411	0.00361	CbGpPWpGaD
Acamprosate—GRIN2B—BDNF signaling pathway—CASP3—colon cancer	0.000401	0.00352	CbGpPWpGaD
Acamprosate—GRIN1—BDNF signaling pathway—CTNNB1—colon cancer	0.000396	0.00348	CbGpPWpGaD
Acamprosate—GRIN2C—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—colon cancer	0.000387	0.0034	CbGpPWpGaD
Acamprosate—GRIN2B—BDNF signaling pathway—CTNNB1—colon cancer	0.000386	0.00339	CbGpPWpGaD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—CASP3—colon cancer	0.000386	0.00339	CbGpPWpGaD
Acamprosate—GABRB3—BDNF signaling pathway—APC—colon cancer	0.000385	0.00338	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—MYC—colon cancer	0.000376	0.00331	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—TGFB1—colon cancer	0.000375	0.0033	CbGpPWpGaD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—CTNNB1—colon cancer	0.000372	0.00327	CbGpPWpGaD
Acamprosate—GRIN2A—Neuronal System—BRAF—colon cancer	0.00037	0.00325	CbGpPWpGaD
Acamprosate—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—colon cancer	0.00037	0.00325	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—EGFR—colon cancer	0.000368	0.00323	CbGpPWpGaD
Acamprosate—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—colon cancer	0.000363	0.00319	CbGpPWpGaD
Acamprosate—GRIN2D—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—colon cancer	0.00036	0.00316	CbGpPWpGaD
Acamprosate—GRIN1—BDNF signaling pathway—SRC—colon cancer	0.000358	0.00315	CbGpPWpGaD
Acamprosate—GRIN1—EPH-Ephrin signaling—HRAS—colon cancer	0.000355	0.00312	CbGpPWpGaD
Acamprosate—GRIN2B—BDNF signaling pathway—SRC—colon cancer	0.000349	0.00307	CbGpPWpGaD
Acamprosate—GRIN2B—EPH-Ephrin signaling—HRAS—colon cancer	0.000346	0.00304	CbGpPWpGaD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—EP300—colon cancer	0.000345	0.00304	CbGpPWpGaD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—VEGFA—colon cancer	0.000327	0.00287	CbGpPWpGaD
Acamprosate—GRIN1—Neuronal System—BRAF—colon cancer	0.000323	0.00284	CbGpPWpGaD
Acamprosate—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—colon cancer	0.000317	0.00279	CbGpPWpGaD
Acamprosate—GRIN2B—Neuronal System—BRAF—colon cancer	0.000315	0.00277	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—TP53—colon cancer	0.000309	0.00272	CbGpPWpGaD
Acamprosate—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—colon cancer	0.000296	0.0026	CbGpPWpGaD
Acamprosate—GRIN2C—Transmission across Chemical Synapses—HRAS—colon cancer	0.000291	0.00256	CbGpPWpGaD
Acamprosate—GABRB3—Transmission across Chemical Synapses—BRAF—colon cancer	0.000278	0.00244	CbGpPWpGaD
Acamprosate—GABRG2—Transmission across Chemical Synapses—BRAF—colon cancer	0.000273	0.0024	CbGpPWpGaD
Acamprosate—GABRB3—BDNF signaling pathway—CASP3—colon cancer	0.000271	0.00238	CbGpPWpGaD
Acamprosate—GRIN2D—Transmission across Chemical Synapses—HRAS—colon cancer	0.000271	0.00238	CbGpPWpGaD
Acamprosate—GABRB3—BDNF signaling pathway—CTNNB1—colon cancer	0.000261	0.0023	CbGpPWpGaD
Acamprosate—GRIN1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—colon cancer	0.000258	0.00227	CbGpPWpGaD
Acamprosate—GRIN1—BDNF signaling pathway—HRAS—colon cancer	0.000252	0.00221	CbGpPWpGaD
Acamprosate—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—colon cancer	0.000251	0.00221	CbGpPWpGaD
Acamprosate—GRIN2B—BDNF signaling pathway—HRAS—colon cancer	0.000246	0.00216	CbGpPWpGaD
Acamprosate—GABRA1—Transmission across Chemical Synapses—BRAF—colon cancer	0.000239	0.0021	CbGpPWpGaD
Acamprosate—GABRB3—BDNF signaling pathway—SRC—colon cancer	0.000236	0.00208	CbGpPWpGaD
Acamprosate—GRIN2C—Neuronal System—HRAS—colon cancer	0.000223	0.00196	CbGpPWpGaD
Acamprosate—GRIN1—BDNF signaling pathway—AKT1—colon cancer	0.000223	0.00196	CbGpPWpGaD
Acamprosate—GRIN2A—Transmission across Chemical Synapses—HRAS—colon cancer	0.000222	0.00195	CbGpPWpGaD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—CASP3—colon cancer	0.000218	0.00192	CbGpPWpGaD
Acamprosate—GRIN2B—BDNF signaling pathway—AKT1—colon cancer	0.000217	0.00191	CbGpPWpGaD
Acamprosate—GABRB3—Neuronal System—BRAF—colon cancer	0.000213	0.00187	CbGpPWpGaD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—CTNNB1—colon cancer	0.00021	0.00185	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—PPARG—colon cancer	0.00021	0.00184	CbGpPWpGaD
Acamprosate—GABRG2—Neuronal System—BRAF—colon cancer	0.000209	0.00184	CbGpPWpGaD
Acamprosate—GRIN2D—Neuronal System—HRAS—colon cancer	0.000207	0.00182	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—PPARG—colon cancer	0.000205	0.0018	CbGpPWpGaD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—EP300—colon cancer	0.000196	0.00172	CbGpPWpGaD
Acamprosate—GRIN1—Transmission across Chemical Synapses—HRAS—colon cancer	0.000194	0.0017	CbGpPWpGaD
Acamprosate—GRIN2B—Transmission across Chemical Synapses—HRAS—colon cancer	0.000189	0.00166	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—SRC—colon cancer	0.000187	0.00164	CbGpPWpGaD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—VEGFA—colon cancer	0.000185	0.00163	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—FGFR3—colon cancer	0.000185	0.00163	CbGpPWpGaD
Acamprosate—GABRA1—Neuronal System—BRAF—colon cancer	0.000183	0.00161	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—SRC—colon cancer	0.000182	0.0016	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—VEGFA—colon cancer	0.000182	0.0016	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—NRAS—colon cancer	0.00018	0.00158	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—VEGFA—colon cancer	0.000178	0.00156	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—NRAS—colon cancer	0.000176	0.00154	CbGpPWpGaD
Acamprosate—GRIN2A—Neuronal System—HRAS—colon cancer	0.00017	0.0015	CbGpPWpGaD
Acamprosate—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—colon cancer	0.00017	0.00149	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—APC—colon cancer	0.00017	0.00149	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—NRAS—colon cancer	0.00017	0.00149	CbGpPWpGaD
Acamprosate—GABRB3—Transmembrane transport of small molecules—ABCB1—colon cancer	0.000169	0.00149	CbGpPWpGaD
Acamprosate—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—colon cancer	0.000167	0.00147	CbGpPWpGaD
Acamprosate—GABRB3—BDNF signaling pathway—HRAS—colon cancer	0.000166	0.00146	CbGpPWpGaD
Acamprosate—GABRG2—Transmembrane transport of small molecules—ABCB1—colon cancer	0.000166	0.00146	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—EGFR—colon cancer	0.000164	0.00144	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—EGFR—colon cancer	0.00016	0.00141	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—BRAF—colon cancer	0.00016	0.0014	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—KRAS—colon cancer	0.000155	0.00136	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—EGFR—colon cancer	0.000155	0.00136	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—KRAS—colon cancer	0.000151	0.00133	CbGpPWpGaD
Acamprosate—GRIN1—Neuronal System—HRAS—colon cancer	0.000148	0.0013	CbGpPWpGaD
Acamprosate—GRM5—GPCR downstream signaling—PIK3CA—colon cancer	0.000148	0.0013	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—CTNNB1—colon cancer	0.000148	0.0013	CbGpPWpGaD
Acamprosate—GABRB3—BDNF signaling pathway—AKT1—colon cancer	0.000147	0.00129	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—KRAS—colon cancer	0.000146	0.00128	CbGpPWpGaD
Acamprosate—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—colon cancer	0.000146	0.00128	CbGpPWpGaD
Acamprosate—GABRA1—Transmembrane transport of small molecules—ABCB1—colon cancer	0.000145	0.00128	CbGpPWpGaD
Acamprosate—GRIN2B—Neuronal System—HRAS—colon cancer	0.000145	0.00127	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—CTNNB1—colon cancer	0.000144	0.00127	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—EP300—colon cancer	0.000137	0.00121	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—PIK3CA—colon cancer	0.000134	0.00118	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—EP300—colon cancer	0.000134	0.00118	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—SRC—colon cancer	0.000134	0.00117	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—HRAS—colon cancer	0.000132	0.00116	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—SRC—colon cancer	0.00013	0.00114	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—VEGFA—colon cancer	0.00013	0.00114	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—NRAS—colon cancer	0.000129	0.00113	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—HRAS—colon cancer	0.000128	0.00113	CbGpPWpGaD
Acamprosate—GABRB3—Transmission across Chemical Synapses—HRAS—colon cancer	0.000128	0.00112	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—VEGFA—colon cancer	0.000127	0.00111	CbGpPWpGaD
Acamprosate—GABRG2—Transmission across Chemical Synapses—HRAS—colon cancer	0.000126	0.0011	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—NRAS—colon cancer	0.000125	0.0011	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—HRAS—colon cancer	0.000124	0.00109	CbGpPWpGaD
Acamprosate—GRM5—GPCR downstream signaling—AKT1—colon cancer	0.000121	0.00106	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—CASP3—colon cancer	0.00012	0.00105	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—TGFB1—colon cancer	0.000119	0.00105	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—EGFR—colon cancer	0.000117	0.00103	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—CCND1—colon cancer	0.000117	0.00102	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—TGFB1—colon cancer	0.000116	0.00102	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—CTNNB1—colon cancer	0.000115	0.00101	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—EGFR—colon cancer	0.000114	0.001	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—CDKN1A—colon cancer	0.000113	0.00099	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—KRAS—colon cancer	0.000111	0.000972	CbGpPWpGaD
Acamprosate—GABRA1—Transmission across Chemical Synapses—HRAS—colon cancer	0.00011	0.000964	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—AKT1—colon cancer	0.00011	0.000964	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—KRAS—colon cancer	0.000108	0.000947	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—EP300—colon cancer	0.000107	0.000942	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—SRC—colon cancer	0.000104	0.000916	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—VEGFA—colon cancer	0.000102	0.000893	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—NRAS—colon cancer	0.0001	0.000882	CbGpPWpGaD
Acamprosate—GABRB3—Neuronal System—HRAS—colon cancer	9.8e-05	0.000861	CbGpPWpGaD
Acamprosate—GABRG2—Neuronal System—HRAS—colon cancer	9.62e-05	0.000845	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—HRAS—colon cancer	9.4e-05	0.000826	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—MYC—colon cancer	9.35e-05	0.000821	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—TGFB1—colon cancer	9.32e-05	0.000819	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—HRAS—colon cancer	9.16e-05	0.000805	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—EGFR—colon cancer	9.14e-05	0.000803	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—KRAS—colon cancer	8.64e-05	0.000759	CbGpPWpGaD
Acamprosate—GABRA1—Neuronal System—HRAS—colon cancer	8.41e-05	0.000739	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—AKT1—colon cancer	8.3e-05	0.000729	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—AKT1—colon cancer	8.09e-05	0.000711	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—PIK3CA—colon cancer	7.93e-05	0.000697	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—TP53—colon cancer	7.67e-05	0.000674	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—HRAS—colon cancer	7.34e-05	0.000645	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—AKT1—colon cancer	6.48e-05	0.00057	CbGpPWpGaD
